-- Study met primary endpoint and all key secondary endpoints with statistically significant and clinically meaningful reductions in weight ...
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. Study met primary endpoint and all ...
BROCKTON — For health and fitness centers, the beginning of a new year is always the busiest time as people ...
AB SCIENCE COMMUNICATES RESULTS FROM PHASE 2B/3 STUDY EVALUATING MASITINIB IN ALZHEIMER’S DISEASE Paris, December 18, 2020, 8.30am CET ...
NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for ...
The highest dose of the once-weekly investigational GLP-1 receptor agonist tirzepatide helped people with type 2 diabetes achieve a ...
December 09, 2020 1 min read ADD TOPIC TO EMAIL ALERTS Receive an email ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and ...
Interim analysis results from the double-blind, phase 3 ADAURA trial demonstrated that among patients with stage IB to IIIA ...
Whiteford/Patton Say Edwardsville Is Prepared For Return to Phase 4 | RiverBender.com ...
